Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Myeloid Differentiation in Myelodysplastic Neoplasms and Leukemic Cells: Role of Azacitidine and Direct Contact with Mesenchymal Stromal Cells

Eleonora Ceneri, Irene Casalin, Alessia De Stefano, Alessandra Cappellini, Lucio Cocco, Stefano Ratti, Lucia Manzoli, Michele Cavo, Miriam Fogli, Sarah Parisi, Stefania Paolini, Marilena Ciciarello, Antonio Curti, Carlo Finelli, Matilde Yung Follo

Blood (2024) 144 (Supplement 1): 6688.

https://doi.org/10.1182/blood-2024-204876

Published: 2024

Journal Articles

Investigating Phosphoinositide-Related and Apoptotic Pathways in Azacitidine and Venetoclax Combination Therapy in Higher-Risk Myelodysplastic Neoplasms and Leukemic Cell Lines

Irene Casalin, Eleonora Ceneri, Alessia De Stefano, Alessandra Cappellini, Andrea Pellagatti, Jacqueline Boultwood, Michele Cavo, Stefano Ratti, Lucia Manzoli, Lucio Cocco, Anna Ferrari, Giorgia Simonetti, Giovanni Martinelli, Miriam Fogli, Stefania Paolini, Sarah Parisi, Antonio Curti, Carlo Finelli, Matilde Yung Follo

Blood (2024) 144 (Supplement 1): 6686.

https://doi.org/10.1182/blood-2024-200842

Published: 2024

Journal Articles

Absolute Lymphocyte Count As a Novel Prognostic Predictor Compared to Minimal Residual Disease and Molecular Status in Patients with Acute Myeloid Leukemiatreated with Intensive Chemotherapy

Gianluca Cristiano, Jacopo Nanni, Letizia Zannoni, Federico Zingarelli, Federica Ardizzoia, Chiara Sartor, Sarah Parisi, Stefania Paolini, Cristina Papayannidis, Michele Cavo, Antonio Curti

Blood (2024) 144 (Supplement 1): 6116.

https://doi.org/10.1182/blood-2024-209333

Published: 2024

Journal Articles

T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2916.

https://doi.org/10.1182/blood-2024-205994

Published: 2024

Journal Articles

Bone Marrow Microenvironment As a Potential Key Regulator of Hematopoietic Cells Stemness in Myelodysplastic Syndromes (MDS)

Irene Casalin, Alessia De Stefano, Alessandra Cappellini, Eleonora Ceneri, Martina Lops, Andrea Pellagatti, Jacqueline Boultwood, Michele Cavo, Stefano Ratti, Lucia Manzoli, Lucio Cocco, Marilena Ciciarello, Miriam Fogli, Stefania Paolini, Sarah Parisi, Antonio Curti, Carlo Finelli, Matilde Yung Follo

Blood (2023) 142 (Supplement 1): 6463.

https://doi.org/10.1182/blood-2023-179914

Published: 2023

Journal Articles

T Cell/Natural Killer (NK) Cell Transcriptional Profiles Are Associated with Response to Gilteritinib in FLT3 -Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2947.

https://doi.org/10.1182/blood-2023-184741

Published: 2023

Journal Articles

Impact of MTHFR Polymorphisms C677T and A1298C in Acute Lymphoblastic Leukemia and Burkitt Lymphoma Patients Exposed to Methotrexate and Asparaginase

Chiara Sartor, Benedetta Pagano, Soara Menabò, Gianluca Cristiano, Jacopo Nanni, Letizia Zannoni, Federico Zingarelli, Sarah Parisi, Alessandro Broccoli, Stefania Paolini, Pier Luigi Zinzani, Michele Cavo, Cristina Papayannidis, Antonio Curti

Blood (2023) 142 (Supplement 1): 5812.

https://doi.org/10.1182/blood-2023-189495

Published: 2023

Journal Articles

Venetoclax Rapidly and Strongly Enhances the Phospholipase C Response to Azacitidine Therapy in Myelodysplastic Syndromes

Matilde Y Follo, Alessia De Stefano, Sara Mongiorgi, Irene Casalin, Alessandra Cappellini, Stefano Ratti, Andrea Pellagatti, Miriam Fogli, Michele Cavo, Lucia Manzoli, Lucio Cocco, Jacqueline Boultwood, Sarah Parisi, Stefania Paolini, Antonio Curti, Carlo Finelli

Blood (2022) 140 (Supplement 1): 6905–6906.

https://doi.org/10.1182/blood-2022-163628

Published: 2022

Journal Articles

Absolute Lymphocyte Count Is an Independent Survival Predictor in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy

Gianluca Cristiano, Jacopo Nanni, Letizia Zannoni, Federico Zingarelli, Chiara Sartor, Sarah Parisi, Stefania Paolini, Cristina Papayannidis, Michele Cavo, Antonio Curti

Blood (2022) 140 (Supplement 1): 11793–11794.

https://doi.org/10.1182/blood-2022-167035

Published: 2022

Journal Articles

A Chemo-Free Bridge-to-Transplant Strategy with Venetoclax and Azacitidine for NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure

Chiara Sartor, Lorenzo Brunetti, Ernesta Audisio, Alessandro Cignetti, Letizia Zannoni, Gianluca Cristiano, Jacopo Nanni, Emanuela Ottaviani, Lorenza Bandini, Sarah Parisi, Stefania Paolini, Sofia Sciabolacci, Valeria Cardinali, Cristina Papayannidis, Michele Cavo, Maria Paola Martelli, Antonio Curti

Blood (2022) 140 (Supplement 1): 9034–9035.

https://doi.org/10.1182/blood-2022-165914

Published: 2022

Journal Articles

IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease

Giovanni Marconi, Lorenza Bandini, Agnese Patuelli, Chiara Sartor, Sarah Parisi, Jacopo Nanni, Gianluca Cristiano, Letizia Zannoni, Giorgia Simonetti, Maria Teresa Bochicchio, Emanuela Ottaviani, Giovanni Martinelli, Stefania Paolini, Cristina Papayannidis, Michele Cavo, Antonio Curti

Blood (2021) 138 (Supplement 1): 4446.

https://doi.org/10.1182/blood-2021-149450

Published: 2021

Journal Articles

An Outpatient Management for First Cycle of Venetoclax and Hypomethylating Agents Results in Reduced Infection Rate and Hospitalizations in Acute Myeloid Leukemia Patients

Jacopo Nanni, Cristina Papayannidis, Gianluca Cristiano, Giovanni Marconi, Chiara Sartor, Sarah Parisi, Rashed Saed, Letizia Zannoni, Emanuela Ottaviani, Lorenza Bandini, Nicoletta Testoni, Carmen Baldazzi, Paolo Ricci, Chiara Di Giovanni Bezzi, Rania Abd-alatif, Stefania Paolini, Michele Cavo, Antonio Curti

Blood (2021) 138 (Supplement 1): 2340.

https://doi.org/10.1182/blood-2021-149535

Published: 2021

Journal Articles

Impact of Comorbidities on Prognosis of Elderly Patients with Acute Myeloid Leukemia Who Receive Hypomethylating Agents

Blood (2021) 138 (Supplement 1): 3373.

https://doi.org/10.1182/blood-2021-149459

Published: 2021

Journal Articles

Role of Mir-192-5p during Response to Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes

Matilde Y Follo, Alessia De Stefano, Sara Mongiorgi, Valentina Indio, Annalisa Astolfi, Stefano Ratti, Andrea Pellagatti, Miriam Fogli, Andrea Pession, Michele Cavo, Lucia Manzoli, Lucio Cocco, Jacqueline Boultwood, Sarah Parisi, Stefania Paolini, Carlo Finelli

Blood (2021) 138 (Supplement 1): 3673.

https://doi.org/10.1182/blood-2021-149183

Published: 2021

Journal Articles

A Three-Gene Immune Signature Including IDO1 , BIN1 and PLXNC1 Predicts Survival in Acute Myeloid Leukemia

Simone Ragaini, MD, Sarah Wagner, BSc MSc, Giovanni Marconi, MD, Sarah Parisi, MDPhD, Chiara Sartor, MD, Jacopo Nanni, MD, Gianluca Cristiano, MD, Annalisa Talami, MD, Matteo Olivi, MD, Darina Ocadlikova, PhD, Marilena Ciciarello, PhD, Giulia Corradi, PhD, Emanuela Ottaviani, Cristina Papayannidis, MDPhD, Stefania Paolini, MD PhD, Jayakumar Vadakekolathu, PhD, Michele Cavo, Sergio Rutella, MDPhDFRCPath, Antonio Curti, MDPhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-139665

Published: 2020

Journal Articles

Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes

Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Alessia De Stefano, BSc, Valentina Indio, PhD, Annalisa Astolfi, PhD, Andrea Pellagatti, Stefano Ratti, MD, Miriam Fogli, PhD, Sarah Parisi, MDPhD, Andrea Pession, Michele Cavo, Lucia Manzoli, MD, Lucio Cocco, MD, Jacqueline Boultwood, Carlo Finelli

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-136942

Published: 2020

Journal Articles

Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses

Blood (2020) 136 (Supplement 1): 45.

https://doi.org/10.1182/blood-2020-138371

Published: 2020

Journal Articles

Venetoclax Plus Hypomethylating Agents for Relapsed/Refractory Acute Myeloid Leukemia (AML) Is Safe and Manageable in the Outpatient Setting

Jacopo Nanni, MD, Cristina Papayannidis, MD PhD, Gianluca Cristiano, MD, Giovanni Marconi, MD, Chiara Sartor, MD, Sarah Parisi, MDPhD, Emanuela Ottaviani, Lorenza Baldini, MSc, Nicoletta Testoni, Carmen Baldazzi, PhD, Paolo Ricci, MD, Chiara Di Giovanni Bezzi, MD, Rania Abd-alatif, MD, Stefania Paolini, MD PhD, Michele Cavo, Antonio Curti, MDPhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-138719

Published: 2020

Journal Articles

The Use of Venetoclax for Acute Myeloid Leukemia in a Real-Life Setting: A Multicenter National Experience

Blood (2019) 134 (Supplement_1): 5098.

https://doi.org/10.1182/blood-2019-128583

Published: 2019

Journal Articles

An IDO1 -Related 3-Gene Signature Predicts Overall Survival in Intermediate-Risk Acute Myeloid Leukemia

Simone Ragaini, MD, Sarah Wagner, BSc MSc, Giovanni Marconi, Sarah Parisi, MD PhD, Chiara Sartor, MD, Jacopo Nanni, MD, Gianluca Cristiano, Annalisa Talami, MD, Matteo Olivi, MD, Darina Ocadlikova, PhD, Marilena Ciciarello, PhD, Giulia Corradi, PhD, Emanuela Ottaviani, Cristina Papayannidis, Stefania Paolini, MD PhD, Jayakumar Vadakekolathu, PhD, Michele Cavo, Sergio Rutella, MD PhD FRCPath, Antonio Curti, MD PhD

Blood (2019) 134 (Supplement_1): 5193.

https://doi.org/10.1182/blood-2019-128348

Published: 2019

NARROW

Myeloid Differentiation in Myelodysplastic Neoplasms and Leukemic Cells: Role of Azacitidine and Direct Contact with Mesenchymal Stromal Cells

Investigating Phosphoinositide-Related and Apoptotic Pathways in Azacitidine and Venetoclax Combination Therapy in Higher-Risk Myelodysplastic Neoplasms and Leukemic Cell Lines

Absolute Lymphocyte Count As a Novel Prognostic Predictor Compared to Minimal Residual Disease and Molecular Status in Patients with Acute Myeloid Leukemiatreated with Intensive Chemotherapy

T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia

Bone Marrow Microenvironment As a Potential Key Regulator of Hematopoietic Cells Stemness in Myelodysplastic Syndromes (MDS)

T Cell/Natural Killer (NK) Cell Transcriptional Profiles Are Associated with Response to Gilteritinib in FLT3 -Mutated Acute Myeloid Leukemia

Impact of MTHFR Polymorphisms C677T and A1298C in Acute Lymphoblastic Leukemia and Burkitt Lymphoma Patients Exposed to Methotrexate and Asparaginase

Venetoclax Rapidly and Strongly Enhances the Phospholipase C Response to Azacitidine Therapy in Myelodysplastic Syndromes

Absolute Lymphocyte Count Is an Independent Survival Predictor in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy

A Chemo-Free Bridge-to-Transplant Strategy with Venetoclax and Azacitidine for NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure

IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease

An Outpatient Management for First Cycle of Venetoclax and Hypomethylating Agents Results in Reduced Infection Rate and Hospitalizations in Acute Myeloid Leukemia Patients

Impact of Comorbidities on Prognosis of Elderly Patients with Acute Myeloid Leukemia Who Receive Hypomethylating Agents

Role of Mir-192-5p during Response to Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes

A Three-Gene Immune Signature Including IDO1 , BIN1 and PLXNC1 Predicts Survival in Acute Myeloid Leukemia

Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes

Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses

Venetoclax Plus Hypomethylating Agents for Relapsed/Refractory Acute Myeloid Leukemia (AML) Is Safe and Manageable in the Outpatient Setting

The Use of Venetoclax for Acute Myeloid Leukemia in a Real-Life Setting: A Multicenter National Experience

An IDO1 -Related 3-Gene Signature Predicts Overall Survival in Intermediate-Risk Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only